EPIDEMIOLOGICAL PROFILE AND CLINICAL OUTCOMES OF SNAKEBITE CASES IN THE TRIBAL REGION OF SOUTHERN RAJASTHAN

Authors

  • Dr. Pintu Ahari
  • Dr. Arun Kumar Meena
  • Dr. Pranay Ahari
  • Dr. Vijay Kumar Meena

DOI:

https://doi.org/10.53555/hrsc5q80

Keywords:

Snakebite, Tribal, Epidemiology, Clinical outcomes.

Abstract

Snakebite remains a significant public health concern, particularly in tribal and rural regions of southern Rajasthan. This retrospective study analyzes snakebite cases reported at Government Medical College, Dungarpur, from 2021 to 2025. Data on demographic distribution, seasonal trends, geographical patterns, and clinical outcomes were compiled and statistically analyzed. The majority of cases were reported from rural areas and involved males of working age, with peak incidence during monsoon months. Despite timely interventions, fatalities were noted, underscoring the need for enhanced awareness and early treatment. This study highlights critical epidemiological trends essential for targeted public health strategies and improved snakebite management in tribal populations.

Author Biographies

  • Dr. Pintu Ahari

    Associate Professor, Dept. of General Medicine, Govt. Medical College, Dungarpur (Rajasthan).

  • Dr. Arun Kumar Meena

    Assistant Professor, Dept. of General Medicine, Govt. Medical College, Dungarpur (Rajasthan).

  • Dr. Pranay Ahari

    Assistant Professor, Dept. of General Surgery, Govt. Medical College, Dungarpur (Rajasthan).

  • Dr. Vijay Kumar Meena

    Assistant Professor, Dept. of General Medicine, Govt. Medical College, Dungarpur (Rajasthan).

References

1. Kasturiratne A, et al. The global burden of snakebite: A literature analysis and modelling based on regional estimates. PLOS Med. 2008; 5:e218.

2. Mohapatra B, et al. Snakebite mortality in India: A Nationally Representative Mortality Survey. PLoS Negl Trop Dis. 2011;5(4):e1018.

3. Simpson ID, Norris RL. Snakes of medical importance: Is the concept of big four still relevant? Wilderness Environ Med. 2007;18:2-9.

4. Warrell DA. Guidelines for the clinical management of snakebites. WHO, Geneva, 2010.

5. Paul V, et al. High-dose versus low-dose ASV in snake bites. J Assoc Physicians India. 2004;52:14-7.

6. Tariang DD, et al. Effective dose of ASV in systemic envenomation. J Assoc Physicians India. 1999;47(4):369-71.

7. Agrawal A, et al. ASV dose in neuroparalytic snake bite. Ann Thorac Med. 2011;6(1):47–48.

8. Indian National Snakebite Protocols 2007. Neurotoxic envenomation. Pg. 21.

9. Seneviratne U, Dissanayake S. Neurological manifestations in Sri Lanka. J Postgrad Med. 2002;48(4):275-78.

10. Sharma N, et al. Snake envenomation in North India. Emerg Med J. 2005;22(2):118-20.

11. Kulakarni ML, Anees S. Snake venom poisoning: Experience with 633 patients. Indian Pediatr. 1994;31(10):1239-43.

12. Harsoor SS, et al. Ventilatory management in neuroparalytic envenomation. Indian J Anaesth. 2006;50(6):452–455.

13. Fernando P, Dias S. Indian krait poisoning. Ceylon Med J. 1982;27(1):39-41.

14. Anil A, et al. Role of neostigmine and ASV in krait bite. J Infect Public Health. 2010;3:83-7.

15. Malasit P, Warrell DA, et al. Antivenom reaction mechanisms. Br Med J. 1986;292:17-20.

16. Cupo P, et al. Hypersensitivity to antivenin sera. Rev Inst Med Trop Sao Paulo. 1991;33:115–22.

17. Agarwal PN, et al. Respiratory failure in neuroparalytic envenomation. Neurol India. 2001;49:25-31.

Downloads

Published

2025-07-04

How to Cite

Dr. Pintu Ahari, Dr. Arun Kumar Meena, Dr. Pranay Ahari, & Dr. Vijay Kumar Meena. (2025). EPIDEMIOLOGICAL PROFILE AND CLINICAL OUTCOMES OF SNAKEBITE CASES IN THE TRIBAL REGION OF SOUTHERN RAJASTHAN. Journal of Population Therapeutics and Clinical Pharmacology, 32(6), 55-59. https://doi.org/10.53555/hrsc5q80
More Citation Formats

Issue

Section

Articles

How to Cite

Dr. Pintu Ahari, Dr. Arun Kumar Meena, Dr. Pranay Ahari, & Dr. Vijay Kumar Meena. (2025). EPIDEMIOLOGICAL PROFILE AND CLINICAL OUTCOMES OF SNAKEBITE CASES IN THE TRIBAL REGION OF SOUTHERN RAJASTHAN. Journal of Population Therapeutics and Clinical Pharmacology, 32(6), 55-59. https://doi.org/10.53555/hrsc5q80